NCT02456038View on ClinicalTrials.gov

Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Hypophosphatasia
Interventions
DRUG

Asfotase Alfa (ALXN1215)

Trial Locations (12)

830-0011

Kurume University Hospital, Kurume

502-8558

National Hospital Organization Nagara Medical Center, Gifu

734-8551

Hiroshima University Hospital, Hiroshima

060-8648

Hokkaido University Hospital, Sapporo

980-8574

Tohoku University Hospital, Sendai

951-8510

Niigata University Medical & Dental Hospital, Niigata

594-1101

Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi

565-0871

Osaka University Hospital, Suita

339-0077

Saitama Children's Medical Center, Saitama

431-3192

Hamamatsu University Hospital, Hamamatsu

113-8603

Nippon Medical School Hospital, Bunkyo-ku

187-8510

Showa General Hospital, Kodaira

All Listed Sponsors
collaborator

Osaka University Graduate School of Medicine

UNKNOWN

lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

NCT02456038 - Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) | Biotech Hunter | Biotech Hunter